FEATURE: Corning Applies New Technology to Microarrays, but Still Faces Obstacles | GenomeWeb

NEW YORK, May 9 - As a June deadline for commercializing its 10,000 gene human microarrays looms, Corning’s Microarray Technology division is finding out what Affymetrix already knows: It’s tougher than you think to make a highly reproducible high-density microarray.

“We are still working the bugs out of the process, and working through the internal validation,” said Thomas Hinman, division vice president and general manager of CMT Life Sciences. “It has taken us longer than we wanted to.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.